Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients

K. V. Rolston; D. H. Ho; B. LeBlanc; G. P. Bodey

doi:10.1007/BF01969529

Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients

K. V. Rolston, D. H. Ho, B. LeBlanc, G. P. Bodey

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The in vitro activity of dirithromycin (LY-237216), a new macrolide erythromycin derivative, was compared to that of four other agents (clarithromycin, erythromycin, roxithromycin, clindamycin) against 334 gram-positive isolates obtained from cancer patients. Dirithromycin was similar in potency and antimicrobial spectrum to the other agents tested. It was very active against beta-haemolytic streptococci and Streptococcus pneumoniae, and moderately active against penicillin and methicillin susceptible Staphylococcus aureus, Bacillus spp., Listeria monocytogenes and Corynebacterium jeikeium. Erythromycin resistant organisms were also resistant to dirithromycin.

Original language	English (US)
Pages (from-to)	30-33
Number of pages	4
Journal	European Journal of Clinical Microbiology & Infectious Diseases
Volume	9
Issue number	1
DOIs	https://doi.org/10.1007/BF01969529
State	Published - Jan 1990

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1007/BF01969529

Cite this

@article{c6fe38c9394646d9ba690808949fbb98,

title = "Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients",

abstract = "The in vitro activity of dirithromycin (LY-237216), a new macrolide erythromycin derivative, was compared to that of four other agents (clarithromycin, erythromycin, roxithromycin, clindamycin) against 334 gram-positive isolates obtained from cancer patients. Dirithromycin was similar in potency and antimicrobial spectrum to the other agents tested. It was very active against beta-haemolytic streptococci and Streptococcus pneumoniae, and moderately active against penicillin and methicillin susceptible Staphylococcus aureus, Bacillus spp., Listeria monocytogenes and Corynebacterium jeikeium. Erythromycin resistant organisms were also resistant to dirithromycin.",

author = "Rolston, {K. V.} and Ho, {D. H.} and B. LeBlanc and Bodey, {G. P.}",

year = "1990",

month = jan,

doi = "10.1007/BF01969529",

language = "English (US)",

volume = "9",

pages = "30--33",

journal = "European Journal of Clinical Microbiology & Infectious Diseases",

issn = "0934-9723",

publisher = "Vieweg",

number = "1",

}

TY - JOUR

T1 - Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients

AU - Rolston, K. V.

AU - Ho, D. H.

AU - LeBlanc, B.

AU - Bodey, G. P.

PY - 1990/1

Y1 - 1990/1

N2 - The in vitro activity of dirithromycin (LY-237216), a new macrolide erythromycin derivative, was compared to that of four other agents (clarithromycin, erythromycin, roxithromycin, clindamycin) against 334 gram-positive isolates obtained from cancer patients. Dirithromycin was similar in potency and antimicrobial spectrum to the other agents tested. It was very active against beta-haemolytic streptococci and Streptococcus pneumoniae, and moderately active against penicillin and methicillin susceptible Staphylococcus aureus, Bacillus spp., Listeria monocytogenes and Corynebacterium jeikeium. Erythromycin resistant organisms were also resistant to dirithromycin.

AB - The in vitro activity of dirithromycin (LY-237216), a new macrolide erythromycin derivative, was compared to that of four other agents (clarithromycin, erythromycin, roxithromycin, clindamycin) against 334 gram-positive isolates obtained from cancer patients. Dirithromycin was similar in potency and antimicrobial spectrum to the other agents tested. It was very active against beta-haemolytic streptococci and Streptococcus pneumoniae, and moderately active against penicillin and methicillin susceptible Staphylococcus aureus, Bacillus spp., Listeria monocytogenes and Corynebacterium jeikeium. Erythromycin resistant organisms were also resistant to dirithromycin.

UR - http://www.scopus.com/inward/record.url?scp=0025100885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025100885&partnerID=8YFLogxK

U2 - 10.1007/BF01969529

DO - 10.1007/BF01969529

M3 - Article

C2 - 2137413

AN - SCOPUS:0025100885

SN - 0934-9723

VL - 9

SP - 30

EP - 33

JO - European Journal of Clinical Microbiology & Infectious Diseases

JF - European Journal of Clinical Microbiology & Infectious Diseases

IS - 1

ER -

Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this